Exhibit 99.1 News | --- | --- | |---------------------------------------------------------------------------|--------------------------------------------------------------------------------| | | | | FOR IMMEDIATE RELEASE | | | Media Contact Information: Sandy Pound Thermo Fisher Scientific | Investor Contact Information: Rafael Tejada Thermo Fisher Scientific | | Phone: 781-622-1223 | Phone: 781-622-1356 | | E-mail: sandy.pound@thermofisher.com | E-mail: rafael.tejada@thermofisher.com | Thermo Fisher Scient ...

Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Lab Consumables - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Lab Consumables is estimated at US$12.7 Million in 2023 and is projected to reach US$17.2 Million by 2030, growing at a CAGR of 4.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The manufacturing and supply of l ...

In its upcoming report, Thermo Fisher Scientific (TMO) is predicted by Wall Street analysts to post quarterly earnings of $5.25 per share, reflecting a decline of 7.7% compared to the same period last year. Revenues are forecasted to be $10.64 billion, representing a year-over-year increase of 0.7%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed t ...

The market expects Thermo Fisher Scientific (TMO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 23, 2024, might help the stock move higher if these ...

Thermo Fisher Scientific Inc. (TMO) is slated to release third-quarter 2024 results on Oct. 23, before market open. Thermo Fisher's second-quarter earnings of $5.37 per share beat the Zacks Consensus Estimate by 4.7%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.98%. TMO's Q3 Estimates The Zacks Consensus Estimate for revenues is pegged at $10.64 billion, suggesting 0.6% growth from the prioryear quarter's reported figure. The consensus mark for earnin ...

Thermo Fisher Scientific Inc. (TMO) is making robust progress with its growth strategy, which bodes well for the upcoming quarters. The spree of innovative product introductions bolsters its portfolio. The company's Bioproduction business is expanding and increasing its capacity to meet the rising demand. Meanwhile, the adverse macroeconomic impacts and currency fluctuations raise concerns for TMO's operations, In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 20.7% compared with th ...

Thermo Fisher Scientific Inc. (NYSE: TMO ) has been one of the best-performing stocks over the last decade, with shares returning more than 420% over this period. I've written about investing for Seeking Alpha since 2015 and for Sure Dividend since 2018. I focus primarily on owning shares of companies that have demonstrated long histories of dividend growth. These types of companies have largely proven successful at raising dividends through multiple recessionary periods, a sign that their business models a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Thermo Fisher Scientific (TMO) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. When looking at the last two reports, this maker of scientific instrument and laboratory supplies has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 6.70%, on average, in the ...

Thermo Fisher Scientific (TMO) announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients. The registry fills a significant gap for real-world evidence and adolescentspecific developmental and safety data related to novel therapies for AD, complementing the existing adult CorEvitas AD Registry launched in 2020. CorEvitas, acquired in August 2023, is part of Thermo Fi ...

文章核心观点 - 电子显微镜业务和战略收购是推动Thermo Fisher Scientific (TMO)增长的主要因素 [1][2][3][4] - 但宏观经济问题和汇率波动持续抑制业务增长 [5][6] 行业和公司研究 推动增长的因素 - 在制药和生物技术市场,公司的生物科学和生物生产业务大幅扩大产能,以满足全球疫苗制造需求 [2] - 公司的制药服务业务为制药和生物技术客户提供开发和生产疫苗和疗法所需的服务 [2] - 在学术和政府以及工业和应用市场,公司的电子显微镜业务实现强劲增长,得益于重大产品发布 [2] - 在诊断和医疗保健市场,尽管与COVID-19检测相关的收入下降,但公司报告了核心收入增长,主要来自移植诊断和免疫诊断业务以及医疗市场渠道 [2] - 公司通过战略收购技术和业务来扩张,增强现有产品和服务 [3][4] - 近期收购Olink Holdings、CorEvitas和MarqMetrix等公司,有助于推动未来增长 [3][4] 潜在风险 - 宏观经济压力、地缘政治局势、供应链和劳动力市场问题给公司业务环境带来挑战 [5] - 国际市场占公司收入的很大比重,汇率波动可能影响公司的收入和盈利 [6]